Ventures

MindAffect is redefining what’s possible in diagnostics. By harnessing Brain-Computer Interface technology and AI, we can “read” how the brain reacts to sound and visual stimuli—objectively, in real time, and without requiring a single response from the patient. At the core is our patented and clinically validated Rapid CAEP® technology, which captures the brain’s automatic reactions. This breakthrough allows clinicians to diagnose patients who would otherwise be difficult or impossible to test—such as infants, seniors, and individuals with disabilities. In a world where over two billion people are underserved by current diagnostic methods, this changes everything. Our first product, Sofi, is the world’s fastest objective hearing diagnostic system, delivering accurate hearing thresholds in minutes. Sofi has been validated in leading hospitals, championed by key opinion leaders across the audiology community, and recognized globally—winning the Innovation Award at the World Congress of Audiology

Nicolab tackles the challenge of stroke diagnosis and treatment by offering computational support through their portfolio of six algorithms. These algorithms analyze radiological images of acute stroke patients, providing fast and objective interpretation for physicians. With stroke affecting millions annually and significant economic burdens, Nicolab's solution improves decision-making speed and accuracy, allowing clinicians to assess stroke severity objectively and make timely treatment decisions.

SERDA presents a solution for wound debridement, particularly useful for burn wounds and chronic wounds like diabetic foot ulcers. Traditional debridement methods can be expensive, painful, or less effective. SERDA offers an enzymatic debrider in the form of a hydrogel that selectively breaks down necrotic tissue, leaving healthy tissue intact, promoting faster healing with minimal discomfort for the patient. SERDA aims to improve the efficiency and ease of wound care, providing a more effective alternative to existing options.

Axial Orthopaedics Inc. revolutionizes trauma treatment with their innovative intramedullary nailing system. Current systems often lead to bone misalignment and joint pain, blocking post-procedural recovery. Axial Orthopaedics's modular system offers greater flexibility in bone alignment and healing. This system not only addresses postoperative pain but also reduces complications. Its intra-operative modularity and rotational capabilities allow surgeons to achieve better fracture fixation and improved outcomes, filling a crucial gap in current technology.

Allergios revolutionizes allergy diagnosis by directly visualizing the allergic response in patient blood, offering a more accurate alternative to current tests like skin prick and IgE blood tests. Additionally by analyzing how blood serum reacts to allergens. With its disposable chip, optical reader, and AI-based analysis software, Allergios helps millions of allergy sufferers worldwide access timely and effective treatment options.

RetinaCheck has developed automated diabetic retinopathy screening software that combines brain-inspired geometric methods and CNNs to analyse fundus camera images. It targets the large undetected burden of early diabetic eye damage in China, where roughly 11.6% of the population has type 2 diabetes and retinopathy is the leading cause of new working-age blindness. The software is now widely used across the country.

DiaphOne TX is developing a first-in-class, orally available small-molecule therapy targeting the RAGE/DIAPH1 pathway, a central but underexploited disease axis in chronic metabolic and inflammatory conditions including type 2 diabetes, obesity and MASH. While existing treatments manage symptoms, they fail to address underlying disease progression. DiaphOne TX's approach targets the root of metabolic stress, inflammation and fibrosis, in a single platform with applicability across multiple high-value, multi-billion-euro markets.

With over 50 million people living with Alzheimer's and numbers expected to triple by 2050, there's an urgent need for effective treatments. Alzheimer's is a leading cause of death and imposes a global economic burden of $1 trillion annually. Our novel DYRK1A inhibitor aims to slow or even reverse Alzheimer's progression by targeting key pathways with high specificity and effective blood-brain barrier penetration. This innovative small molecule offers superior disease-modifying potential, addressing current treatment limitations and providing new hope for patients and healthcare systems worldwide.